Download PDF
Semin Respir Crit Care Med 2015; 36(04): 470-477
DOI: 10.1055/s-0035-1555608
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Alpha-1 Antitrypsin Deficiency

Charlie Strange
1   Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, Charleston, South Carolina
,
Tatsiana Beiko
1   Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, Charleston, South Carolina
› Author Affiliations
Further Information

Publication History

Publication Date:
03 August 2015 (online)

    Permissions and Reprints

Abstract

Alpha-1 antitrypsin deficiency (AATD) is a rare genetic disease that creates multiple unique phenotypes of chronic obstructive pulmonary disease. While bronchospasm, cough, dyspnea, and sputum production all occur with AATD, the phenotypic differences require a computed tomographic (CT) scan to decipher. The availability of augmentation therapy in the United States since 1989 has generated both controversy and evidence that informs the science of usual chronic obstructive pulmonary disease (COPD). Because of the predominance of emphysema in AATD, much of the best evidence concerning biomarkers of emphysema progression comes from this population. Imaging measurement of emphysema progression, impact of emphysema phenotypes on hyperinflation and dynamic hyperinflation, and correlation with traditional spirometric measures of COPD progression are required to understand the impact of AAT therapies. These studies are important for better understanding of usual COPD pathogenesis. Significantly, there are no adequately powered research studies to determine if augmentation therapy is helpful for the non-emphysema phenotypes of AATD. Specifically, phenotypes of chronic bronchitis, asthma predominant disease, and bronchiectasis will require targeted research studies to define optimal therapy.

Keywords

antitrypsin - COPD - emphysema - genetic disease - bronchiectasis - asthma - lung transplant - augmentation
 

  • References

  • 1 Laurell CB, Eriksson S. The electrophoretic α1-globulin pattern of serum in α1-antitrypsin deficiency. 1963. COPD 2013; 10 (Suppl. 01) 3-8
    CrossrefPubMedGoogle Scholar
  • 2 Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003. Chest 2005; 128 (3) 1179-1186
    CrossrefPubMedGoogle Scholar
  • 3 Bernspång E, Sveger T, Piitulainen E. Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency. Respir Med 2007; 101 (9) 1971-1976
    CrossrefPubMedGoogle Scholar
  • 4 Curiel DT, Chytil A, Courtney M, Crystal RG. Serum alpha 1-antitrypsin deficiency associated with the common S-type (Glu264----Val) mutation results from intracellular degradation of alpha 1-antitrypsin prior to secretion. J Biol Chem 1989; 264 (18) 10477-10486
    PubMedGoogle Scholar
  • 5 Hubbard RC, McElvaney NG, Sellers SE, Healy JT, Czerski DB, Crystal RG. Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency. J Clin Invest 1989; 84 (4) 1349-1354
    CrossrefPubMedGoogle Scholar
  • 6 Hubbard RC, Fells G, Gadek J, Pacholok S, Humes J, Crystal RG. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 1991; 88 (3) 891-897
    CrossrefPubMedGoogle Scholar
  • 7 Bergin DA, Reeves EP, Meleady P , et al. α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest 2010; 120 (12) 4236-4250
    CrossrefPubMedGoogle Scholar
  • 8 Mahadeva R, Atkinson C, Li Z , et al. Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 2005; 166 (2) 377-386
    CrossrefPubMedGoogle Scholar
  • 9 Carroll TP, Greene CM, O'Connor CA, Nolan AM, O'Neill SJ, McElvaney NG. Evidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiency. J Immunol 2010; 184 (8) 4538-4546
    CrossrefPubMedGoogle Scholar
  • 10 Tosi MF, Zakem H, Berger M. Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest 1990; 86 (1) 300-308
    CrossrefPubMedGoogle Scholar
  • 11 Hartl D, Latzin P, Hordijk P , et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007; 13 (12) 1423-1430
    CrossrefPubMedGoogle Scholar
  • 12 Fick Jr RB, Naegel GP, Squier SU, Wood RE, Gee JB, Reynolds HY. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest 1984; 74 (1) 236-248
    CrossrefPubMedGoogle Scholar
  • 13 Smallman LA, Hill SL, Stockley RA. Reduction of ciliary beat frequency in vitro by sputum from patients with bronchiectasis: a serine proteinase effect. Thorax 1984; 39 (9) 663-667
    CrossrefPubMedGoogle Scholar
  • 14 Guyot N, Butler MW, McNally P , et al. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J Biol Chem 2008; 283 (47) 32377-32385
    CrossrefPubMedGoogle Scholar
  • 15 Taggart CC, Lowe GJ, Greene CM , et al. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem 2001; 276 (36) 33345-33352
    CrossrefPubMedGoogle Scholar
  • 16 Miller SD, Greene CM, McLean C , et al. Tauroursodeoxycholic acid inhibits apoptosis induced by Z alpha-1 antitrypsin via inhibition of Bad. Hepatology 2007; 46 (2) 496-503
    CrossrefPubMedGoogle Scholar
  • 17 Brantly ML, Paul LD, Miller BH, Falk RT, Wu M, Crystal RG. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis 1988; 138 (2) 327-336
    CrossrefPubMedGoogle Scholar
  • 18 Tobin MJ, Cook PJ, Hutchison DC. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Dis Chest 1983; 77 (1) 14-27
    CrossrefPubMedGoogle Scholar
  • 19 Janus ED, Phillips NT, Carrell RW. Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet 1985; 1 (8421) 152-154
    PubMedGoogle Scholar
  • 20 McElvaney NG, Stoller JK, Buist AS , et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1997; 111 (2) 394-403
    CrossrefPubMedGoogle Scholar
  • 21 Dawkins PA, Dowson LJ, Guest PJ, Stockley RA. Predictors of mortality in alpha1-antitrypsin deficiency. Thorax 2003; 58 (12) 1020-1026
    CrossrefPubMedGoogle Scholar
  • 22 Seersholm N, Kok-Jensen A. Survival in relation to lung function and smoking cessation in patients with severe hereditary alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med 1995; 151 (2, Pt 1): 369-373
    CrossrefPubMedGoogle Scholar
  • 23 Needham M, Stockley RA. Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax 2004; 59 (5) 441-445
    CrossrefPubMedGoogle Scholar
  • 24 Eden E, Mitchell D, Mehlman B , et al. Atopy, asthma, and emphysema in patients with severe alpha-1-antitrypysin deficiency. Am J Respir Crit Care Med 1997; 156 (1) 68-74
    CrossrefPubMedGoogle Scholar
  • 25 Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand 1978; 204 (5) 345-351
    PubMedGoogle Scholar
  • 26 Guest PJ, Hansell DM. High resolution computed tomography (HRCT) in emphysema associated with alpha-1-antitrypsin deficiency. Clin Radiol 1992; 45 (4) 260-266
    CrossrefPubMedGoogle Scholar
  • 27 King MA, Stone JA, Diaz PT, Mueller CF, Becker WJ, Gadek JE. Alpha 1-antitrypsin deficiency: evaluation of bronchiectasis with CT. Radiology 1996; 199 (1) 137-141
    CrossrefPubMedGoogle Scholar
  • 28 Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2007; 176 (12) 1215-1221
    CrossrefPubMedGoogle Scholar
  • 29 Gadek JE, Klein HG, Holland PV, Crystal RG. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981; 68 (5) 1158-1165
    CrossrefPubMedGoogle Scholar
  • 30 Ziomek CA. Commercialization of proteins produced in the mammary gland. Theriogenology 1998; 49 (1) 139-144
    CrossrefPubMedGoogle Scholar
  • 31 Wright G, Carver A, Cottom D , et al. High level expression of active human alpha-1-antitrypsin in the milk of transgenic sheep. Biotechnology (N Y) 1991; 9 (9) 830-834
    PubMedGoogle Scholar
  • 32 Casolaro MA, Fells G, Wewers M , et al. Augmentation of lung antineutrophil elastase capacity with recombinant human alpha-1-antitrypsin. J Appl Physiol (1985) 1987; 63 (5) 2015-2023
    PubMedGoogle Scholar
  • 33 Wewers MD, Casolaro MA, Sellers SE , et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316 (17) 1055-1062
    CrossrefPubMedGoogle Scholar
  • 34 Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158 (1) 49-59
    CrossrefPubMedGoogle Scholar
  • 35 Seersholm N, Wencker M, Banik N , et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997; 10 (10) 2260-2263
    CrossrefPubMedGoogle Scholar
  • 36 Dawkins PA, Dawkins CL, Wood AM, Nightingale PG, Stockley JA, Stockley RA. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33 (6) 1338-1344
    CrossrefPubMedGoogle Scholar
  • 37 Dirksen A, Dijkman JH, Madsen F , et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160 (5, Pt 1) 1468-1472
    CrossrefPubMedGoogle Scholar
  • 38 FDA. Blood Product Advisory Committee Issue Summary. 2009 , Rockville, MD
    PubMedGoogle Scholar
  • 39 Coxson HO, Dirksen A, Edwards LD , et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med 2013; 1 (2) 129-136
    CrossrefPubMedGoogle Scholar
  • 40 Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A. Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010; 11: 136
    CrossrefPubMedGoogle Scholar
  • 41 Dirksen A, Piitulainen E, Parr DG , et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33 (6) 1345-1353
    CrossrefPubMedGoogle Scholar
  • 42 Chapman KR, Burdon JGW, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Huang L, Edelman JM, McElvaney NG. IV alpha1 antitrypsin (A1AT) preserves lung density in homozygous alpha1 antitrypsin deficiency (A1ATD); a randomized, placebo-controlled trial. Am J Respir Crit Care Med 2013; 187: A6069
    PubMedGoogle Scholar
  • 43 Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 2009; 360 (26) 2749-2757
    CrossrefPubMedGoogle Scholar
  • 44 Kolodka TM, Finegold M, Kay MA, Woo SL. Hepatic gene therapy: efficient retroviral-mediated gene transfer into rat hepatocytes in vivo. Somat Cell Mol Genet 1993; 19 (5) 491-497
    CrossrefPubMedGoogle Scholar
  • 45 Song S, Morgan M, Ellis T , et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci U S A 1998; 95 (24) 14384-14388
    CrossrefPubMedGoogle Scholar
  • 46 Chulay JD, Ye GJ, Thomas DL , et al. Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method. Hum Gene Ther 2011; 22 (2) 155-165
    CrossrefPubMedGoogle Scholar
  • 47 Chiuchiolo MJ, Kaminsky SM, Sondhi D , et al. Intrapleural administration of an AAVrh.10 vector coding for human α1-antitrypsin for the treatment of α1-antitrypsin deficiency. Hum Gene Ther Clin Dev 2013; 24 (4) 161-173
    CrossrefPubMedGoogle Scholar
  • 48 Brantly ML, Spencer LT, Humphries M , et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006; 17 (12) 1177-1186
    CrossrefPubMedGoogle Scholar
  • 49 Brantly ML, Chulay JD, Wang L , et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A 2009; 106 (38) 16363-16368
    CrossrefPubMedGoogle Scholar
  • 50 Flotte TR, Trapnell BC, Humphries M , et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther 2011; 22 (10) 1239-1247
    CrossrefPubMedGoogle Scholar
  • 51 Loring HS, Flotte TR. Current status of gene therapy for α-1 antitrypsin deficiency. Expert Opin Biol Ther 2015; 15 (3) 329-336
    CrossrefPubMedGoogle Scholar
  • 52 Mueller C, Flotte TR. Gene-based therapy for alpha-1 antitrypsin deficiency. COPD 2013; 10 (Suppl. 01) 44-49
    CrossrefPubMedGoogle Scholar
  • 53 Mueller C, Tang Q, Gruntman A , et al. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol Ther 2012; 20 (3) 590-600
    CrossrefPubMedGoogle Scholar
  • 54 Wencker M, Banik N, Buhl R, Seidel R, Konietzko N. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J 1998; 11 (2) 428-433
    CrossrefPubMedGoogle Scholar
  • 55 Stoller JK, Fallat R, Schluchter MD , et al. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. Chest 2003; 123 (5) 1425-1434
    CrossrefPubMedGoogle Scholar
  • 56 Meyer FJ, Wencker M, Teschler H , et al. Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor. Eur Respir J 1998; 12 (4) 996-997
    CrossrefPubMedGoogle Scholar
  • 57 Stocks JM, Brantly ML, Wang-Smith L , et al. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha1-antitrypsin deficiency: a randomized study. BMC Clin Pharmacol 2010; 10: 13
    PubMedGoogle Scholar
  • 58 Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD 2009; 6 (3) 177-184
    CrossrefPubMedGoogle Scholar
  • 59 Sclar DA, Evans MA, Robison LM, Skaer TL. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained. Clin Drug Investig 2012; 32 (5) 353-360
    CrossrefPubMedGoogle Scholar
  • 60 Gildea TR, Shermock KM, Singer ME, Stoller JK. Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2003; 167 (10) 1387-1392
    CrossrefPubMedGoogle Scholar
  • 61 Hubbard RC, Sellers S, Czerski D, Stephens L, Crystal RG. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA 1988; 260 (9) 1259-1264
    CrossrefPubMedGoogle Scholar
  • 62 Barker AF, Iwata-Morgan I, Oveson L, Roussel R. Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency. Chest 1997; 112 (3) 607-613
    CrossrefPubMedGoogle Scholar
  • 63 Cammarata SK, Stone CL, Carey JL, Eichenhorn MS. Failure to achieve adequate serum levels with monthly replacement therapy in alpha 1-antitrypsin deficiency. Chest 1994; 106 (2) 651-652
    CrossrefPubMedGoogle Scholar
  • 64 Zamora NP, Pla RV, Del Rio PG, Margaleff RJ, Frias FR, Ronsano JB. Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy. Ann Pharmacother 2008; 42 (5) 640-646
    CrossrefPubMedGoogle Scholar
  • 65 Soy D, de la Roza C, Lara B, Esquinas C, Torres A, Miravitlles M. Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. Thorax 2006; 61 (12) 1059-1064
    CrossrefPubMedGoogle Scholar
  • 66 Monk R, Graves M, Williams P, Strange C. Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment. COPD 2013; 10 (4) 411-415
    CrossrefPubMedGoogle Scholar
  • 67 Molloy K, Hersh CP, Morris VB , et al. Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014; 189 (4) 419-427
    CrossrefPubMedGoogle Scholar
  • 68 Sandhaus RA, Turino G, Stocks J , et al; Medical and Scientific Advisory Committee of the Alpha-1 Foundation. alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note. Chest 2008; 134 (4) 831-834
    CrossrefPubMedGoogle Scholar
  • 69 Turino GM, Barker AF, Brantly ML , et al. Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1996; 154 (6, Pt 1) 1718-1725
    CrossrefPubMedGoogle Scholar
  • 70 Trulock EP. Lung transplantation for alpha 1-antitrypsin deficiency emphysema. Chest 1996; 110 (6, Suppl): 284S-294S
    CrossrefPubMedGoogle Scholar
  • 71 King MB, Campbell EJ, Gray BH, Hertz MI. The proteinase-antiproteinase balance in alpha-1-proteinase inhibitor-deficient lung transplant recipients. Am J Respir Crit Care Med 1994; 149 (4, Pt 1) 966-971
    CrossrefPubMedGoogle Scholar
  • 72 Giacoboni D, Barrecheguren M, Esquinas C , et al. Characteristics of candidates for lung transplantation due to chronic obstructive pulmonary disease and alpha-1 antitrypsin deficiency emphysema. Arch Bronconeumol 2014; . PMID 25301410
    PubMedGoogle Scholar
  • 73 Banga A, Gildea T, Rajeswaran J, Rokadia H, Blackstone EH, Stoller JK. The natural history of lung function after lung transplantation for α(1)-antitrypsin deficiency. Am J Respir Crit Care Med 2014; 190 (3) 274-281
    PubMedGoogle Scholar
  • 74 Stoller JK, Gildea TR, Ries AL, Meli YM, Karafa MT ; National Emphysema Treatment Trial Research Group. Lung volume reduction surgery in patients with emphysema and alpha-1 antitrypsin deficiency. Ann Thorac Surg 2007; 83 (1) 241-251
    CrossrefPubMedGoogle Scholar
  • 75 Hillerdal G, Mindus S. One- to four-year follow-up of endobronchial lung volume reduction in alpha-1-antitrypsin deficiency patients: a case series. Respiration 2014; 88 (4) 320-328
    CrossrefPubMedGoogle Scholar
  • 76 Tuohy MM, Remund KF, Hilfiker R, Murphy DT, Murray JG, Egan JJ. Endobronchial valve deployment in severe α-1 antitrypsin deficiency emphysema: a case series. Clin Respir J 2013; 7 (1) 45-52
    CrossrefPubMedGoogle Scholar
  • 77 Kamada Press Release. Available at: www.kamada.com/press_item.php?ID=101 . Accessed 2014
    PubMedGoogle Scholar
  • 78 Chan ED, Kaminska AM, Gill W , et al. Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages. Scand J Infect Dis 2007; 39 (8) 690-696
    CrossrefPubMedGoogle Scholar
  • 79 Yang P, Sun Z, Krowka MJ , et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med 2008; 168 (10) 1097-1103
    CrossrefPubMedGoogle Scholar